Research also indicated that panobinostat, another HDAC inhibitor, enhances trastuzumab’s efficacy by triggering a CXCR3-mediated NK cell and IFNγ-dependent immune response in breast cancer [120]. Here, HDAC9 is linked to breast cancer.